Our Company
Zentalis develops small molecule therapeutics with differentiated product profiles for a broad range of cancers.
Utilizing our Integrated Discovery Engine, the Company is developing a focused pipeline of potentially best-in-class oncology candidates, which include azenosertib, a WEE1 inhibitor for advanced solid tumors. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in San Diego.

Julie Eastland
Chief Executive Officer, President and Director

Julie Eastland
Chief Executive Officer, President and Director
Management Team
Julie is the Chief Executive Officer and Director at Zentalis. Prior to joining Zentalis, she served as the Chief Executive Officer and President of Harpoon Therapeutics, a publicly traded clinical stage oncology company, from November 2021, and a member of its Board of Directors from October 2018, until its acquisition by Merck Sharpe & Dohme in March of 2024. Julie previously served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, a privately held genetics medicine company. Prior to ReCode, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, a privately held biopharmaceutical company focused on bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, a publicly traded oncology company acquired by Seattle Genetics in 2018. Prior to Cascadian, Julie served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Julie is an independent director of Dynavax Technologies Corporation, Lantheus, and Seismic Therapeutic. Julie received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.

Ingmar Bruns, M.D.,
Chief Medical Officer

Ingmar Bruns, M.D.,
Chief Medical Officer
Management Team
Ingmar is Chief Medical Officer of Zentalis. He brings two decades of hematology and oncology experience as a physician and scientist. Prior to joining Zentalis, Ingmar served as Chief Medical Officer of Trillium Therapeutics, a publicly traded clinical stage oncology company, through its acquisition by Pfizer in November 2021, after which he served in clinical development roles at Pfizer, most recently as Development Head, Hematologic Malignancies, Pfizer Global Product Development. Ingmar previously served as the Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals, a publicly traded clinical stage biotechnology company, where he built and led the clinical development organization. From 2013 through 2017, he led clinical development of several high priority oncology assets at Bayer Pharmaceuticals. Previously, Ingmar served as an attending hematologist and oncologist as well as a physician-scientist at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Ingmar has authored over 50 publications in the field of hematology and oncology, including several lead authorships in high impact journals such as Nature Medicine, Blood and Leukemia. He received his M.D. and Ph.D. from the University of Lubeck in Germany.

Wendy Chang
Chief People Officer

Wendy Chang
Chief People Officer
Management Team
Wendy is the Chief People Officer of Zentalis. She brings over two decades of biopharma experience, including senior roles in human resources and an extensive background in aligning talent with organizations’ overall vision and direction. She was previously Chief People Officer at Harpoon Therapeutics. Before Harpoon, she was VP, Head of People & Culture for IDbyDNA. Wendy previously served in roles of increasing responsibility at Gilead Sciences from 2003 to 2020, most recently as Vice President, Human Resources, and, earlier in her career, at Bio-Rad Laboratories. She received a B.S. in accounting and business/management from the University of California, Riverside, and completed the Global Fellow of Talent Management program at The Wharton School of the University of Pennsylvania.

Andrea Paul, JD
Chief Legal Officer and Corporate Secretary

Andrea Paul, JD
Chief Legal Officer and Corporate Secretary
Management Team
Andrea Paul is Chief Legal Officer and Corporate Secretary at Zentalis Pharmaceuticals. Previously, Andrea served as General Counsel and Corporate Secretary of LogicBio Therapeutics, Inc., where she led the company’s legal team and served as a key strategic legal partner in the company’s finance, business development and contractual decision-making matters. Before that, she held positions of increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of Vice President, Legal. While at Akebia, Andrea was a key strategic legal partner in the company’s merger with Keryx Biopharmaceuticals, Inc. as well as in the company’s financing and business development transactions. Prior to Akebia, she served as Senior Corporate Counsel at Momenta Pharmaceuticals, Inc. She began her legal career working as an associate at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Sullivan and Cromwell LLP. She received her JD from Harvard Law School, where she served as the Managing Editor of The Harvard Law Review, and her BA in Art History from Columbia University.
Interesting Fact: Andrea is a dedicated Michael Schumacher fan and still watches replays of his F1 races.

Haibo Wang
Chief Business Officer

Haibo Wang
Chief Business Officer
Management Team
Haibo is the Chief Business Officer of Zentalis. He brings over 15 years of biopharma business development, finance, and M&A transaction experience, having most recently served as Senior Vice President of Business Development at Harpoon Therapeutics. While at Harpoon, he played a pivotal role in managing the Company’s acquisition by Merck, which was completed in March 2024. Prior to Harpoon, he served as the Vice President of Business Development at Hummingbird Bioscience, where he was responsible for the company’s end-to-end business development activities. Prior to Hummingbird, Haibo was Director of Business Development at Amgen, where he played a major role in the Teneobio and Five Prime Therapeutics acquisitions, the oncology collaboration with BeiGene, and many clinical collaborations to advance Amgen’s oncology pipeline. He began his career as an M&A consultant at Deloitte, advising on transactions in healthcare and technology. Haibo holds an M.S. in Biotechnology from Johns Hopkins University, an MBA from Duke University, and a BBA from Tsinghua University.

Robert DiVasto, P.E.
Senior Vice President, Technical Operations

Robert DiVasto, P.E.
Senior Vice President, Technical Operations
Management Team
Bob is Senior Vice President of Technical Operations and Head of CMC at Zentalis Pharmaceuticals. He brings over 30 years of international pharmaceutical and biopharmaceutical experience in the design, implementation and operation of global supply chains for both commercial and investigational products. Prior to joining Zentalis, Bob served as Senior Vice President, Manufacturing and Supply for Zavante Therapeutics (acquired by Nabrivia Therapeutics in 2018), a late clinical-stage pharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. Previously, Bob served as Vice President, Manufacturing and Supply for Cadence Pharmaceuticals. During his tenure, he developed and implemented the outsourced supply strategy for OFIRMEV® (acetaminophen) focusing on supply security and speed to market. Prior to Cadence, Bob was Vice President, European Supply at Valeant Pharmaceuticals in Basel, Switzerland, where he oversaw the global manufacturing and supply at the Company’s four major factories. Over the course of his career, he has held several senior operations and engineering roles, including at GlaxoSmithKline in the US and UK. Bob received his MSc in Manufacturing from the University of Cambridge, England and BS in Environmental Engineering from Temple University. He is a registered Professional Engineer (P.E.) and is a contributing member of the International Society of Pharmaceutical Engineers (ISPE).

Henry Gu
Senior Vice President, Head of Intellectual Property

Henry Gu
Senior Vice President, Head of Intellectual Property
Management Team
Henry Gu is Senior Vice President, Head of Intellectual Property at Zentalis Pharmaceuticals, bringing over two decades of experience in patent procurement, due diligence, strategic IP counseling, and litigation. Prior to joining Zentalis, Henry held increasingly senior roles at several biopharmaceutical companies, including Morphic Therapeutic, Akebia Therapeutics, ARIAD Pharmaceuticals, and Cubist Pharmaceuticals. At Akebia, Henry played a pivotal role in the company’s merger with Keryx Biopharmaceuticals and was a key legal partner in major strategic collaborations with Otsuka Pharmaceutical and Mitsubishi Tanabe Pharma. He also led multiple ANDA litigations related to Auryxia®, successfully negotiating favorable settlements with generic challengers to extend market exclusivity. While at ARIAD, Henry was responsible for securing global IP protections across commercial, clinical, and discovery-stage assets. He was part of the core team that executed the company’s $5.2 billion acquisition by Takeda Pharmaceuticals. At Cubist, he managed the global patent portfolio for Cubicin®, the company’s blockbuster antibiotic, through its acquisition by Merck for $10 billion in 2015. Earlier in his career, Henry was Counsel at WilmerHale, where he advised Fortune 100 biopharmaceutical companies on complex IP matters. He began his legal career in-house at Bristol-Myers Squibb, after starting in the industry as a medicinal chemist. He holds a J.D. from Rutgers University School of Law, an M.S. in Organic Chemistry from Ohio University, and a B.S. in Applied Chemistry from Shanghai Jiao Tong University.

Rajesh Israni
Senior Vice President, Regulatory Affairs & Medical Writing

Rajesh Israni
Senior Vice President, Regulatory Affairs & Medical Writing
Management Team
Rajesh is the Head of Regulatory, Biometrics, and Medical Writing at Zentalis, bringing over two decades of leadership in advancing oncology and immuno-oncology therapies. A passionate regulatory strategist, Rajesh has successfully guided multiple innovative treatments through global approval by developing and executing high-impact regulatory pathways. He has held senior roles at Bristol Myers Squibb, Sanofi, Seagen, and Dragonfly Therapeutics, where he built and led high-performing teams with a strong emphasis on mentorship and organizational growth. Rajesh has also spearheaded key strategic partnerships with major pharmaceutical companies, including Gilead, BMS, Merck, and AbbVie. While at Seagen, he played a pivotal role in establishing several successful collaborations, notably a global in-licensing and co-development agreement for a key oncology asset. Bringing deep expertise in regulatory strategy and biometrics, combined with a collaborative leadership style, Rajesh plays a key role in advancing the development and approval of new therapies. He holds a Master of Science in Biotechnology and Genomics from Rutgers University and a Master of Science in Information Systems from Stevens Institute of Technology, with a specialization in digital strategy for life sciences. He earned his Bachelor of Engineering from Amravati University in India.

Vincent Vultaggio
Senior Vice President, Finance & Principal Accounting Officer

Vincent Vultaggio
Senior Vice President, Finance & Principal Accounting Officer
Management Team
Vince joined Zentalis as Controller/Senior Director, Finance in September 2020 and was subsequently promoted to Executive Director, Finance and Controller in January 2021, Vice President, Finance, in February 2023 and Senior Vice President and Principal Accounting Officer in July 2024. Before joining the Company, Mr. Vultaggio held roles of various responsibilities at life science and technology companies. Mr. Vultaggio began his career at Ernst & Young LLP, where he was a Manager, Assurance Services from September 2004 through April 2011. Mr. Vultaggio received a B.A. in Accountancy and an M.A. in Accountancy and Financial Management from the University of San Diego in 2004.
Board of Directors
Julie Eastland
Chief Executive Officer and Director
Julie Eastland
Chief Executive Officer and Director
Board of Directors
Julie is the Chief Executive Officer and Director at Zentalis. Prior to joining Zentalis, she served as the Chief Executive Officer and President of Harpoon Therapeutics, a publicly traded clinical stage oncology company, from November 2021, and a member of its Board of Directors from October 2018, until its acquisition by Merck Sharpe & Dohme in March of 2024. Julie previously served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, a privately held genetics medicine company. Prior to ReCode, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, a privately held biopharmaceutical company focused on bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, a publicly traded oncology company acquired by Seattle Genetics in 2018. Prior to Cascadian, Julie served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Julie is an independent director of Dynavax Technologies Corporation, Lantheus, and Seismic Therapeutic. Julie received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.
Dave Johnson
Director
Dave Johnson
Director
Board of Directors
Dave has more than 25 years of experience in the biopharmaceutical industry. Most recently, he was chairman of the preclinical precision oncology-focused company, Lengo Therapeutics, which was acquired by Blueprint Medicines in December 2021 in a transaction valued at up to $465M. Prior to Lengo, Dave was CEO of VelosBio an oncology-focused biopharmaceutical company that he founded in December 2017. VelosBio created novel monoclonal antibody-based therapeutics, rapidly moving its lead ROR1-directed antibody-drug-conjugate zilovertamab vedotin from pre-IND through Phase 1 clinical validation leading to the company’s acquisition by Merck in December 2020 for $2.75B. Before Velos, Dave was with Acerta Pharma, an oncology-focused pharmaceutical company focused on covalent small-molecule technology, where he rose to CEO. At Acerta, he built out all facets of the corporation to accelerate the development of Bruton tyrosine kinase inhibitor, acalabrutinib (Calquence™), rapidly moving from early- to late-stage clinical development and launching four global registration-directed trials, including the accelerated approval study that led to acalabrutinib’s first regulatory approval. Dave’s tenure at Acerta culminated in the execution of a strategic transaction with AstraZeneca valued at $7B. He qualifies as an “independent” director in accordance with the listing requirements of Nasdaq.
Enoch Kariuki, PharmD
Director
Enoch Kariuki, PharmD
Director
Board of Directors
Enoch is an accomplished executive with over a decade of experience in healthcare strategy, life sciences investment banking, venture capital and business development. He currently serves as the President of Endeavor BioMedicines. Previously, he served as Chief Executive Officer of Lengo Therapeutics (acquired by Blueprint Medicines) and as the Chief Financial Officer of VelosBio (acquired by Merck) where he led all finance-related and investor relations functions. Prior to VelosBio, he served as Senior Vice President, Corporate Development at Synthorx, where he led the company’s $151 million IPO, managed relationships with bankers, sell-side equity analysts and investors, and headed the business development process that concluded with the sale of Synthorx to Sanofi for $2.5 billion. Before Synthorx, Enoch was Vice President at H.I.G. Capital, a $40 billion private equity firm, where he invested in and served on the boards of multiple life sciences companies. His other previous roles include Senior Associate at Leerink Partners and Associate Director at UBS Investment Bank. At Leerink and UBS, Enoch advised healthcare companies on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.
Enoch completed a Post-Doctoral Fellowship in R&D Strategy and Analytics at Bristol Myers Squibb and was a Pharmacist at CVS Caremark. He holds an MBA from the Tuck School of Business at Dartmouth College and a PharmD from Texas Southern University. Enoch qualifies as an “independent” director in accordance with the listing requirements of Nasdaq.
Scott Myers
Chairperson
Scott Myers
Chairperson
Board of Directors
Scott has worked in the global pharmaceutical and medical technology industries for nearly three decades. He was Chief Executive Officer, President and Director of Viridian Therapeutics, a publicly traded biotechnology company, until November 2023. He was previously Chief Executive Officer and served on the Board of Directors of AMAG Pharmaceuticals, where he led its turnaround and strategic sale to Covis Pharma, S.à.r.l., a pharmaceutical company. Scott served as Chief Executive Officer and Chairman of the Board of Directors of Rainier Therapeutics where he led Rainier’s asset sale of vofatamab to Fusion Pharmaceuticals. Prior to Rainier, Scott served as Chief Executive Officer, President and Director of Cascadian Therapeutics from April 2016 through its acquisition by Seattle Genetics. Scott also serves as Chairperson of the Boards of Directors of Convergent Therapeutics and Dynavax Technologies Corporation. He previously served on the Boards of Directors of Harpoon Therapeutics, Selecta Biosciences, Trillium Therapeutics, and Ironshore Pharmaceuticals. Scott holds a B.A. in biology from Northwestern University and an M.B.A. from the Graduate School of Business (Booth) at the University of Chicago. Scott qualifies as an “independent” director in accordance with the listing requirements of Nasdaq.
Jan Skvarka, PhD, MBA
Director
Jan Skvarka, PhD, MBA
Director
Board of Directors
Jan is an Executive Chairman at DEM Biopharma, and a member of the Board of Directors at Monte Rosa Therapeutics (Nasdaq:GLUE). Previously, he was the CEO of Trillium Therapeutics (Nasdaq:TRIL), a clinical stage immuno-oncology company, where he led a highly successful, 360-degree turn-around that produced a leading CD47 drug candidate, while taking the company from a $16M valuation to a $2.3B buy-out by Pfizer in two years. Prior to that, Jan was the CEO of Tal Medical, a private, clinical stage neuroscience company; a partner in the life sciences practice at Bain & Company, Boston; and a manager at Price Waterhouse Corporate Finance in London, UK and Vienna, Austria. He holds a PhD in economics from the University of Economics in Slovakia, and an MBA from Harvard Business School. Jan qualifies as an “independent” director in accordance with the listing requirements of Nasdaq.
Karan Takhar
Director
Karan Takhar
Director
Board of Directors
Karan is a Managing Director and the head of Life Sciences investing at Matrix Capital Management, an investment fund focused on technology and life sciences. He received a Bachelor of Science in Economics and Mathematics from the Massachusetts Institute of Technology. Karan qualifies as an “independent” director in accordance with the listing requirements of Nasdaq.
Luke Walker, M.D.
Director
Luke Walker, M.D.
Director
Board of Directors
Dr. Luke Walker is the Chief Medical Officer at Umoja Biopharma, a clinical-stage company in in vivo cell therapies. Before joining Umoja, Dr. Walker served as Chief Medical Officer at Harpoon Therapeutics, where he led the company’s immune-oncology efforts through its acquisition by Merck in 2024. His previous roles include clinical development leadership at Seagen, Cascadian Therapeutics, and Oncothyreon. Earlier in his career, Dr. Walker was a practicing oncologist at The Everett Clinic and completed a hematology-oncology fellowship at Oregon Health & Science University, where he also completed his residency in internal medicine. He earned his M.D. from the University of Oklahoma College of Medicine.
Luke qualifies as an “independent” director in accordance with the listing requirements of Nasdaq.
Scientific Advisory Board
Anthony Letai, MD, PhD
Harvard Medical School
Anthony Letai, MD, PhD
Harvard Medical School
Scientific Advisory Board
Dr. Anthony Letai is Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute. His research focuses on the mechanisms by which cancer cells evade death, and on the application of that knowledge to the selective killing of cancer cells. He joined the faculty of DFCI and Harvard Medical School in 2004. He received his MD and PhD from the University of Chicago. He completed his residency in internal medicine at Brigham and Women’s Hospital, and a fellowship in hematology and oncology at DFCI. He did his postdoctoral research training in the laboratory of Dr. Stanley Korsmeyer.
Ross Levine, MD
Memorial Sloan Kettering Cancer Center
Ross Levine, MD
Memorial Sloan Kettering Cancer Center
Scientific Advisory Board
Dr. Ross Levine is the Director of the Memorial Sloan Kettering Center for Hematologic Malignancies, Laurence Joseph Dineen Chair in Leukemia Research, Member of the Human Oncology and Pathogenesis Program, and Attending Physician at Memorial Sloan Kettering Cancer Center. Dr. Levine’s pioneering research has illuminated the genetic basis of myeloid malignancies, including studies that delineated the role of the JAK-STAT pathway and other oncogenic drivers in the pathogenesis of myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML). His current efforts focus on the role of mutations in epigenetic modifiers in MPN and AML pathogenesis and therapeutic response, investigation of the role of different signaling pathways in hematopoietic transformation, and mechanisms of resistance to targeted therapies in MPN/AML. He received his MD degree from Johns Hopkins University and his BS from Harvard University.
Funda Meric-Bernstam, MD
MD Anderson Cancer Center
Funda Meric-Bernstam, MD
MD Anderson Cancer Center
Scientific Advisory Board
Funda Meric-Bernstam, M.D., is the Chair of the Department of Investigational Cancer Therapeutics — the Phase 1 Program at The University of Texas MD Anderson Cancer Center. She is a widely recognized Phase 1 trial expert and experimental therapeutics researcher in oncology. Dr. Meric-Bernstam’s clinical research is focused on novel therapeutics, combination therapies, and biomarkers to predict and monitor drug response. Dr. Meric-Bernstam received her MD from the Yale University School of Medicine.
Kwok-Kin Wong, MD, PhD
NYU Langone Health
Kwok-Kin Wong, MD, PhD
NYU Langone Health
Scientific Advisory Board
Dr. Kwok-Kin Wong is a Director, Division of Hematology and Medical Oncology, Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine at Laura and Isaac Perlmutter Cancer Center, NYU Langone Health. Dr. Wong obtained his MD, PhD degree at the Columbia University College of Physicians and Surgeons. He was trained in internal medicine at the Massachusetts General Hospital, and hematology and oncology at the Dana-Farber Cancer Institute, both at Harvard Medical School. He was previously the Scientific Director of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute (DFCI)/ Harvard Medical School. He has authored more than 250 papers and has various patents on the molecular biology of cancer and aging. He is a member of the American Society of Clinical Investigation Association of American Physicians, the nation’s oldest honor society for physician-scientists. He also co-founded G1 Therapeutics.